Mivavotinib citrate is a Small Molecule owned by Calithera Biosciences, and is involved in 1 clinical trial, which is ongoing.
Mivavotinib citrate (TAK-659) is a dual FLT3/syk inhibitor. TAK-659 inhibits the activity of syk, which abrogates downstream B-cell receptor (BCR) signaling and leads to an inhibition of B-cell activation, chemotaxis, adhesion and proliferation. Syk is expressed in hematopoietic tissues and is often overexpressed in hematopoietic malignancies, less chemotaxis toward tissue homing chemokines facilitates treatment of cancer.
The revenue for Mivavotinib citrate is expected to reach a total of $4.1bn through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Mivavotinib citrate NPV Report.
Mivavotinib citrate Overview
Mivavotinib citrate (TAK-659) is under development for the treatment of gastric cancer and relapsed or refractory acute myelogenous leukemia (AML). It is administered through oral route. It acts by targeting Syk and FLT3 inhibitor. It was also under development for the treatment of advanced solid tumors such as colon cancer, ovarian cancer, pancreatic cancer, metastatic triple-negative breast cancer, metastatic non-small cell lung cancer, metastatic or recurrent head and neck squamous cell carcinoma, hematological malignancies including diffuse large B-cell lymphoma, chronic lymphocytic leukemia, indolent non-Hodgkin lymphoma (iNHL), marginal zone lymphoma, Waldenstrom macroglobulinemia, follicular lymphoma, post-transplant lymphoproliferative disorder (PTLD) and mantle cell lymphoma.
Calithera Biosciences Overview
Calithera Biosciences (Calithera) is a clinical-stage bio-pharmaceutical company that discovers and develops novel small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer. The company’s product pipeline includes CB-839, a glutaminase inhibitor in tumor metabolism to treat solid tumors, NCB001158, a small molecule arginase inhibitor based on tumor immunology technology that activates the body’s own immune system to attack and kill cancer cells for the treatment of hematology and oncology diseases, CB-280, a arginase inhibitor used for treating Cystic Fibrosis, CB-708, a CD73 inhibitor against immuno-oncology conditions and IL4I1 Inhibitor CB-668 against immuno-oncology conditions. The company works in collaboration with bio-pharmaceutical companies such as Incyte Corp, Bristol-Myers Squibb (BMS), and Mars Symbiosciences Inc. Calithera is headquartered in South San Francisco, California, the US.
The company reported revenues of (US Dollars) US$9.8 million for the fiscal year ended December 2021 (FY2021). The operating loss of the company was US$115.4 million in FY2021, compared to an operating loss of US$91.4 million in FY2020. The net loss of the company was US$115.1 million in FY2021, compared to a net loss of US$90.1 million in FY2020.
Quick View – Mivavotinib citrate
|Highest Development Stage|